Integragen - Asset Resilience Ratio
Integragen (ALINT) has an Asset Resilience Ratio of 1.16% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Integragen's Asset Resilience Ratio has changed over time. Check ALINT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Integragen's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Integragen.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €41.65K | 1.16% |
| Total Liquid Assets | €41.65K | 1.16% |
Asset Resilience Insights
- Limited Liquidity: Integragen maintains only 1.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Integragen Industry Peers by Asset Resilience Ratio
Compare Integragen's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
ZAI LAB LTD0000006
F:1ZLB |
Biotechnology | 0.91% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 34.30% |
Annual Asset Resilience Ratio for Integragen (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Integragen.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.98% | €1.05 Million ≈ $1.22 Million |
€5.51 Million ≈ $6.45 Million |
+5.93pp |
| 2023-12-31 | 13.05% | €1.04 Million ≈ $1.22 Million |
€8.00 Million ≈ $9.35 Million |
-9.64pp |
| 2022-12-31 | 22.69% | €2.05 Million ≈ $2.39 Million |
€9.02 Million ≈ $10.55 Million |
-15.71pp |
| 2021-12-31 | 38.40% | €3.69 Million ≈ $4.31 Million |
€9.60 Million ≈ $11.23 Million |
-54.66pp |
| 2020-12-31 | 93.06% | €8.21 Million ≈ $9.60 Million |
€8.82 Million ≈ $10.31 Million |
+45.40pp |
| 2019-12-31 | 47.67% | €3.22 Million ≈ $3.76 Million |
€6.75 Million ≈ $7.89 Million |
-28.57pp |
| 2018-12-31 | 76.23% | €6.54 Million ≈ $7.65 Million |
€8.58 Million ≈ $10.03 Million |
+11.73pp |
| 2017-12-31 | 64.50% | €5.58 Million ≈ $6.52 Million |
€8.65 Million ≈ $10.11 Million |
+7.12pp |
| 2016-12-31 | 57.38% | €4.35 Million ≈ $5.09 Million |
€7.59 Million ≈ $8.87 Million |
+16.30pp |
| 2015-12-31 | 41.08% | €3.54 Million ≈ $4.14 Million |
€8.62 Million ≈ $10.08 Million |
-8.58pp |
| 2014-12-31 | 49.66% | €4.55 Million ≈ $5.32 Million |
€9.17 Million ≈ $10.72 Million |
+8.35pp |
| 2013-12-31 | 41.31% | €2.39 Million ≈ $2.79 Million |
€5.78 Million ≈ $6.76 Million |
-16.67pp |
| 2012-12-31 | 57.97% | €4.55 Million ≈ $5.32 Million |
€7.85 Million ≈ $9.18 Million |
+0.35pp |
| 2011-12-31 | 57.63% | €4.02 Million ≈ $4.69 Million |
€6.97 Million ≈ $8.15 Million |
-13.25pp |
| 2010-12-31 | 70.87% | €5.80 Million ≈ $6.78 Million |
€8.18 Million ≈ $9.56 Million |
+47.20pp |
| 2009-12-31 | 23.67% | €991.31K ≈ $1.16 Million |
€4.19 Million ≈ $4.90 Million |
+4.14pp |
| 2008-12-31 | 19.53% | €698.59K ≈ $816.73K |
€3.58 Million ≈ $4.18 Million |
-- |
About Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more